Bayer Canada Partners with Mint Pharmaceuticals for ADALAT XL Distribution to Strengthen Canadian Market Access
核心洞察
Bayer Canada (搜索) has formed a strategic partnership with Mint Pharmaceuticals (搜索) Inc. for the distribution of ADALAT XL (nifedipine extended-release tablets) 30 mg tablets in Canada, effective September 3, 2025.
The collaboration leverages Mint's extensive distribution network and 15-year supply chain expertise to ensure uninterrupted access to this cardiovascular medication for Canadian patients and healthcare providers.
ADALAT XL is indicated for managing chronic stable angina (搜索) and mild to moderate essential hypertension (搜索), having received market authorization in Canada in 1995.
Bayer Canada (搜索) has announced a strategic distribution partnership with Mint Pharmaceuticals (搜索) Inc. for ADALAT XL (nifedipine extended-release tablets) 30 mg tablets in Canada, effective September 3, 2025. The collaboration aims to enhance accessibility and availability of this established cardiovascular medication across the Canadian market.
Strategic Partnership Details
The partnership leverages Mint Pharmaceuticals (搜索)' extensive distribution network and supply chain expertise developed over 15 years in the Canadian pharmaceutical market. "We are excited to partner with Mint Pharmaceuticals Inc., a company known for its commitment to quality and customer service," said Viktoria Friedrich, Country President and General Manager at Bayer Inc., Pharmaceutical Division. "This partnership will enable us to leverage Mint's extensive distribution network and expertise in the Canadian market, ensuring that ADALAT XL remains readily available to those who need it."
Jaiveer Singh, Chief Executive Officer of Mint Pharmaceuticals (搜索), emphasized the company's commitment to ensuring uninterrupted medication access. "Canadian patients and healthcare professionals depend on uninterrupted access to vital medicines, and that responsibility drives everything we do at Mint," Singh stated. "By partnering with Bayer, we are reinforcing our shared commitment to reliability, quality, and patient care. With a best-in-class supply chain built over the past 15 years, Mint is proud to bring that strength to the distribution of ADALAT XL, ensuring Canadians have seamless access to this trusted therapy."
ADALAT XL Clinical Profile
ADALAT XL (nifedipine extended-release tablets) first received market authorization in Canada in 1995 and is indicated for the management of chronic stable angina (搜索) and the management of mild to moderate essential hypertension (搜索). The medication represents an established treatment option in the cardiovascular therapeutic landscape, with nearly three decades of clinical use in the Canadian market.
Mint Pharmaceuticals' Supply Chain Strength
Mint Pharmaceuticals (搜索) has demonstrated significant capability in maintaining pharmaceutical supply continuity, having averted 23 national drug shortages across 16 essential medicines over the past decade. The company achieved a major portfolio milestone in 2024 by launching its 100th molecule in Canada, reflecting substantial growth in its pharmaceutical offerings.
The Canadian-owned and operated manufacturer has received recognition from Deloitte as one of Canada's Best Managed Companies for seven consecutive years, achieving Platinum Club status in 2025. Mint Pharmaceuticals (搜索) is also a member company of the Canadian Generic Pharmaceutical Association (CGPA).
Market Impact and Distribution Focus
The collaboration between Bayer Canada (搜索) and Mint Pharmaceuticals (搜索) will focus on maintaining the highest standards of distribution to ensure healthcare professionals and patients can rely on the timely availability of ADALAT XL. Both companies share a dedication to providing high-quality pharmaceutical products and exceptional service to the Canadian healthcare system.
The partnership represents a strategic approach to pharmaceutical distribution that prioritizes supply chain resilience and patient access, particularly important for cardiovascular medications where treatment continuity is essential for patient outcomes.